Alkermes: From Orexin Leader to CNS Powerhouse – A Pivotal Quarter
Q2 2026 results show LUMRYZ integration accelerating, LYBALVI access expanding, and an orexin pipeline stretching into ADHD and fatigue, all as the CEO baton passes.
ALKS · Earnings Call · 2026-07-28
A Handoff at the Helm; a Surge in the Pipeline
Alkermes' Q2 2026 call marked a symbolic and strategic turning point. Richard Pops, who has led the company for decades, capped his final earnings call as CEO with confident optimism: “Alkermes' leadership position in orexin development is now quite clear.” — Richard F. Pops, Chief Executive Officer · 2026-07-28 The baton passes to Blair Jackson, who inherits a company that is, by all measures, executing on all cylinders. The stock's +44.9% rally over the last 90 days (per orexin biology) reflects growing investor conviction in a platform that is rapidly expanding beyond its original narcolepsy focus.Orexin: Beyond Sleep-Wake
While alixorexton remains the flagship, this quarter showcased a deliberate broadening of the orexin franchise. Blair Jackson outlined the strategy:The company is now enrolling a Phase 1b study of ALKS 7290 in adult ADHD, with data expected by the end of Q3, and is planning a Phase 2a in fatigue (MS and Parkinson's) with ALKS 4510. These moves pivot on the idea that significant unmet need exists across a spectrum of CNS disorders. The expansion also leverages the insight that orexin activity can be dose ranging to benefit patients with intact orexin tone, a key differentiation from earlier assumptions. As Rich noted, the ambition is to emulate the GLP-1 playbook: “You start with GLP-1, you add GIP, you add glucagon, you start getting triples and adding this pharmacology into other established pharmacologic pathways in CNS indications is really exciting.” — Richard F. Pops, Chief Executive Officer · 2026-07-28We have built the industry's most comprehensive portfolio of orexin 2 receptor agonists and are now advancing that science across multiple indications where meaningful unmet need remains.
Commercial Execution and Strategic Access
On the commercial side, LUMRYZ delivered net sales of $96.6M in its first full quarter post-Avadel, with ~3,900 patients on therapy. The integration is exceeding expectations. Todd Nichols emphasized the LYBALVI access breakthrough: “Through new contracting arrangements... we expanded access strategically with three of the largest Part D plans where LYBALVI is now on formulary, covering more than 80% of insured lives.” — Todd Nichols, Chief Commercial Officer · 2026-07-28 This is a deliberate trade-off of near-term gross-to-net for long-term volume, and it underscores the company's disciplined approach to brand building. VIVITROL, meanwhile, continues to outperform, and the termination of the Amneal AG deal has removed a near-term competitive threat – a point Rich underscored: “We terminated the Amneal deal earlier this year, so there won't be an authorized generic next year.” — Richard F. Pops, Chief Executive Officer · 2026-07-28 This is a meaningful shift for a product that many had written off.Financial Health and the Path Forward
The financial picture is solid, but not without its wrinkles. Q2 total revenues reached $496M, up 34% in proprietary product sales. Yet, as CFO Joshua Reed explained, the acquisition of Avadel and a non-cash fair value adjustment to the contingent consideration swamped the bottom line, resulting in a GAAP net income of just $0.5M. The company updated its GAAP net loss guidance to $(95-115)M for the year, while reiterating its adjusted EBITDA guidance. Total revenue increased 28% y/y in Q1 (per fundamentals) and accelerated in Q2 to $496M, reflecting the full quarter of LUMRYZ. The balance sheet remains strong with $690M in cash and investments, but leverage is up from the acquisition – liabilities-to-assets jumped to 58.9% from 27.4% a year earlier. That said, the company is deliberately investing in the orexin franchise. As CFO Joshua Reed noted, “R&D expenses were $112.9M, reflecting continued advancement of our orexin portfolio.” — Joshua Reed, Chief Financial Officer · 2026-07-28 The story is also one of building a durable franchise across two complementary mechanisms – oxybate (LUMRYZ) and orexin agonists – positioning Alkermes as a one-stop shop for hypersomnolence disorders. The management team has repeatedly highlighted the potential for combination therapy, and the company is generating evidence to support it.What's Next
The next few quarters are dense with catalysts: the Phase 1b ADHD readout (Q3 2026), the Vibrance-3 IH top-line (Q4 2026), the LUMRYZ sNDA submission for IH (by year-end), and continued Phase 3 enrollment for alixorexton. With a new CEO at the helm, the strategic direction is clear: press the advantage in orexin while harvesting cash from the legacy products. As Rich said in his farewell, “We entered the second half of the year with a series of meaningful clinical readouts ahead of us.” — Richard F. Pops, Chief Executive Officer · 2026-07-28 The market is taking notice.The upcoming months will test whether Alkermes can translate its pipeline promise into commercial reality. But the pieces are in place: a robust clinical franchise, a committed team, and a market that finally sees the magnitude of the opportunity."Our objective is simple: deliver on the tremendous opportunities ahead of us, focusing on what matters most, operating with discipline and executing with excellence." – Blair Jackson, incoming CEO